AI synthesis of six filings for Amgen Inc.
Sources: the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (accession 0000318154-26-000010, filed February 13, 2026); the Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (accession 0000318154-26-000155, filed November 4, 2026); and Forms 8-K as cited in each section.
Business
From the FY2025 Form 10-K (accession 0000318154-26-000010), unless otherwise noted.
Amgen discovers, develops, manufactures and sells medicines, mostly biologics, for serious illnesses in cardiovascular and bone health, rare diseases, inflammation and oncology. It also sells biosimilars of other companies' biologics. Almost all of its revenue is product sales: in 2025 product sales were $35.1 billion of $36.8 billion in total revenues, and the remaining $1.6 billion of "other revenues" was mainly royalty income and revenue from corporate partners. The United States generated 73% of 2025 product sales ($25.7 billion) and the rest of the world 27% ($9.5 billion), with Europe the largest market outside the United States. Amgen reports a single operating segment, human therapeutics, and has a presence in approximately 100 countries.
How it sells. In the United States substantially all sales go to pharmaceutical wholesalers. Three of them, McKesson, Cencora and Cardinal Health, together accounted for 77% of worldwide gross revenues in 2025. Outside the United States Amgen sells mainly to healthcare providers and wholesalers. Net prices are set through government programs (Medicare, Medicaid, the 340B Program) and negotiations with commercial insurers and PBMs, and rebates and discounts account for much of the gap between list and net price. Amgen also sells Repatha, Aimovig and AMJEVITA directly to patients through its AmgenNow program.
Portfolio. The 2025 sales base was spread across 14 principal products, none above 13% of product sales:
| Product (2025) | Product sales | Change vs 2024 | What it treats |
|---|---|---|---|
| Prolia | $4.41B | +1% | Osteoporosis (denosumab) |
| Repatha | $3.02B | +36% | LDL cholesterol / cardiovascular risk (PCSK9 inhibitor) |
| Otezla | $2.27B | +7% | Psoriasis, psoriatic arthritis (oral PDE4 inhibitor) |
| ENBREL | $2.23B | -33% | Rheumatoid arthritis, psoriasis (U.S. and Canada only) |
| EVENITY | $2.10B | +34% | Osteoporosis (romosozumab; partnered with UCB) |
| XGEVA | $2.08B | -6% | Bone complications of cancer (denosumab) |
| TEPEZZA | $1.90B | +3% | Thyroid eye disease |
| BLINCYTO | $1.56B | +28% | B-cell acute lymphoblastic leukemia (CD19 BiTE) |
| Nplate | $1.52B | +5% | Immune thrombocytopenia |
| TEZSPIRE | $1.48B | +52% | Severe asthma, nasal polyps (co-developed with AstraZeneca) |
| KYPROLIS | $1.41B | -6% | Multiple myeloma |
| Aranesp | $1.39B | +4% | Anemia |
| KRYSTEXXA | $1.34B | +13% | Chronic refractory gout |
| Vectibix | $1.18B | +12% | Colorectal cancer |
| Other products | $7.26B | +29% | Includes PAVBLU, UPLIZNA, IMDELLTRA, MVASI, AMJEVITA, TAVNEOS, Neulasta, LUMAKRAS, WEZLANA and others |
By the third quarter of 2026 Amgen counted UPLIZNA and IMDELLTRA/IMDYLLTRA among its principal products (10-Q, accession 0000318154-26-000155). Its earnings releases group the portfolio into General Medicine (Repatha, EVENITY, Prolia), Rare Disease (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS and ultra-rare products), Inflammation (TEZSPIRE, Otezla, ENBREL and the AMJEVITA, PAVBLU and WEZLANA biosimilars), Oncology (BLINCYTO, IMDELLTRA, Vectibix, KYPROLIS, LUMAKRAS, Nplate, XGEVA, MVASI) and Established Products (Aranesp, Neulasta, Parsabiv) (Form 8-K, accession 0000318154-26-000153). Amgen has launched eight biosimilars since 2018, including PAVBLU (a biosimilar of EYLEA) and, in 2025, WEZLANA (STELARA) and BKEMV (SOLIRIS) in the United States.
Exclusivity. The RANKL-antibody patents covering Prolia and XGEVA expired in February 2025 in the United States and in November 2025 in select European countries, and multiple denosumab biosimilars have since launched. Other dates from the 10-K patent table:
- EVENITY: U.S. antibody patent listed as expiring April 25, 2026; formulation and method patents run to 2031–2033.
- KRYSTEXXA: U.S. polypeptide patent listed as expiring April 11, 2026; method-of-treatment patents run to 2040.
- Repatha: U.S. antibody patent to August 2029, method patents to 2032.
- Otezla: U.S. compound patent to February 2028, with pediatric exclusivity to August 16, 2028.
- ENBREL: U.S. fusion-protein and DNA patents to 2028–2029, formulation patents to 2037–2038.
- TEPEZZA: U.S. biologic exclusivity to 2032.
Collaborations.
- AstraZeneca (TEZSPIRE): the companies share global costs and profits equally after AstraZeneca pays Amgen a mid-single-digit royalty. Amgen books U.S. sales.
- UCB (EVENITY): UCB leads commercialization in most of Europe and Amgen everywhere else.
- BeOne Medicines (formerly BeiGene): Amgen bought an equity stake in January 2020 for about $2.8 billion. The stake was about 17%, with a fair value of $6.9 billion, at September 30, 2026 (10-Q). BeOne sells XGEVA, BLINCYTO and KYPROLIS in China, and under a November 11, 2025 amendment keeps those rights for as long as the products are sold there.
- Kyowa Kirin (rocatinlimab): in January 2026 Amgen agreed to end the collaboration and hand the program to Kyowa Kirin. Antitrust clearance came in February 2026, and Amgen continues to manufacture rocatinlimab for an agreed transition period.
Manufacturing. Commercial production runs in Puerto Rico, Rhode Island, Ohio, California, Ireland, the Netherlands and Singapore, with a substantial majority in Puerto Rico; most clinical manufacturing is in Thousand Oaks, California. The Horizon acquisition added more than 30 contract manufacturers, many of them single-source. Amgen opened a drug-substance plant in Holly Springs, North Carolina in January 2025, broke ground on a second plant there, and announced expansions in New Albany, Ohio and Puerto Rico. In December 2025, in recognition of this U.S. investment, Amgen received relief from Section 232 pharmaceutical tariffs for approximately three years.
R&D and pipeline. R&D expense was $7.3 billion in 2025, up from $6.0 billion, of which $4.3 billion went to later-stage clinical programs. The main late-stage programs are:
- MariTide (maridebart cafraglutide): a GLP-1 receptor agonist / GIPR antagonist antibody-peptide conjugate for obesity, dosed monthly or less often, with Phase 3 studies in weight management with and without type 2 diabetes, cardiovascular outcomes, heart failure and obstructive sleep apnea.
- Olpasiran: an siRNA that lowers Lp(a), in cardiovascular outcomes trials.
- Xaluritamig: a STEAP1 BiTE for prostate cancer.
- Dazodalibep: a CD40L inhibitor for Sjögren's disease.
- Life-cycle programs: TEZSPIRE in COPD and eosinophilic esophagitis, and IMDELLTRA in earlier-line small cell lung cancer.
- Biosimilar candidates: versions of OPDIVO, KEYTRUDA and OCREVUS.
- Dropped: in February 2026 Amgen said it would not seek approval of bemarituzumab in first-line gastric cancer.
People. About 31,500 staff in more than 50 countries at December 31, 2025, about 13,000 of them outside the United States.
How the portfolio was assembled. Several of today's growth products were bought: Otezla from Bristol Myers Squibb in November 2019; TAVNEOS through the ChemoCentryx acquisition in October 2022; and TEPEZZA, KRYSTEXXA and UPLIZNA through the $27.8 billion acquisition of Horizon Therapeutics on October 6, 2023, funded largely with $24.0 billion of senior notes and a $4.0 billion term loan. The 10-K risk factors also name Dark Blue Therapeutics among Amgen's acquisitions; no filing reviewed here discloses its terms. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987.
Risk factors
From the FY2025 Form 10-K (accession 0000318154-26-000010), Item 1A, as updated by Part II, Item 1A of the Q3 2026 Form 10-Q (accession 0000318154-26-000155).
1. U.S. drug-pricing policy is cutting net prices on named products, and the list is growing.
- IRA Medicare price setting: CMS-set Medicare Part D prices took effect for ENBREL on January 1, 2026 and take effect for Otezla in January 2027, "in each case at significantly lower levels". The Q3 10-Q adds that Repatha may be a candidate for Medicare price setting as early as January 2029. The Part D redesign shifts costs to manufacturers, and several Amgen products have already paid IRA inflation rebates.
- MFN pricing: Amgen received the July 2025 MFN Letter and in December 2025 said it is taking actions that satisfy its components, including MFN pricing requests. It also participates in CMS's GENEROUS Medicaid supplemental-rebate model; in September 2026 CMS said all 50 states, the District of Columbia and Puerto Rico had applied to join. The Administration has asked Congress to write the MFN terms into law, possibly with broader reach.
- 340B Program: expanded use of 340B discounts has already hurt sales. Twenty-three states now have laws imposing mandates on manufacturers in the program, up from twenty at the time of the 10-K. HRSA approved Amgen's participation in a one-year 340B rebate pilot for ENBREL and Otezla starting January 2027, which the company says may not fully address duplicate discounts.
- State PDABs and importation: Colorado's board set an upper payment limit for ENBREL effective no earlier than January 1, 2027, though implementation is preliminarily enjoined. Washington's board selected ENBREL for affordability review in July 2025 and Otezla on September 16, 2026, and cannot set a limit before January 1, 2027. The FDA authorized Colorado's drug-importation program in June 2026, which could affect Amgen's small-molecule products.
- Medicaid funding: the 2025 U.S. tax law ("OB3") is projected to cut federal Medicaid spending significantly and raise the number of uninsured, which Amgen expects to weigh on coverage and which could push 340B use higher.
2. Biosimilar and generic competition.
- Denosumab: Prolia and XGEVA are in "accelerated sales erosion" as multiple biosimilars launch in the United States and abroad.
- Otezla: generics entered certain European countries in the first quarter of 2026.
- Speed of losses: Amgen warns it can lose most of a product's revenue very quickly after exclusivity ends; Sensipar is its own example.
- Regulatory trends: the FDA and EMA increasingly accept biosimilar applications without comparative clinical efficacy trials, and EU regulators treat approved biosimilars as interchangeable, both of which could speed competition. A pending revision of EU pharmaceutical law could shorten data and orphan exclusivity.
3. The IRS transfer-pricing dispute. The IRS says too much profit was allocated to Amgen's Puerto Rico operations.
- 2010–2012: the IRS seeks about $3.6 billion of additional federal tax plus interest, reduced by up to about $900 million of repatriation tax already paid.
- 2013–2015: the IRS seeks about $5.1 billion plus interest and about $2.0 billion of penalties, reduced by up to about $2.2 billion of repatriation tax already paid.
- Tax Court timing: the consolidated case was tried from November 2024 to January 2025, supplemental closing briefs were filed May 20, 2026, and Amgen expects a decision no earlier than late 2026 or early 2027.
- 2016–2018: a draft notice of proposed adjustment (NOPA) arrived in April 2026 and was reissued in substantially the same form in May and July 2026. In September 2026 the IRS sent a draft NOPA asserting penalties for those years substantially similar to the 2013–2015 penalties. The 10-Q says the adjustments and penalties, if sustained in full, "could have a material impact" on the financial statements; Amgen intends to contest them.
- 2019–2022: the IRS began auditing these years in the second quarter of 2026.
- Other tax exposure: the OECD minimum tax, OB3 (foreign earnings taxed at 12.6% from 2026), and tax incentive grants in Puerto Rico (through 2050) and Singapore (through 2036).
4. Regulators can revisit approvals; TAVNEOS is the live case.
- TAVNEOS (avacopan): the FDA asked Amgen on January 16, 2026 to withdraw the drug voluntarily, citing the analysis and adjudication of pivotal-trial data; Amgen declined on January 28. A March 31 Drug Safety Communication flagged serious and fatal liver injury, and on April 27 the FDA's drug center (CDER) proposed withdrawing approval, alleging a lack of substantial evidence of effectiveness and untrue statements in ChemoCentryx's application. Amgen requested a hearing on June 1 and filed supporting data on July 23; CDER had not responded when the Q3 10-Q was filed, and the FDA may decide without a hearing. In August 2026 the European Commission revoked the EU marketing authorization held by a ChemoCentryx licensee, and regulators in other jurisdictions have begun reviews or revocations. The drug stays on the U.S. market while the process runs. Its U.S. intangible asset carried $2.2 billion at September 30, 2026.
- LUMAKRAS: still on accelerated approval after a 2023 Complete Response Letter.
- EVENITY: carries a postmarketing cardiovascular-safety requirement.
- FDA capacity: staffing cuts, leadership changes and government shutdowns could slow reviews.
5. Litigation.
- Regeneron antitrust: in May 2025 a jury found for Regeneron on antitrust and tortious-interference claims over Amgen's bundled contracting of Repatha with ENBREL and Otezla. Damages total $406.8 million under either alternative theory, and the antitrust portion is subject to trebling. As of the 10-K Amgen had not accrued a liability, judging a loss not probable.
- ENBREL patent antitrust: a CareFirst class action, a Sandoz suit and insurer suits in Ventura County, California allege that a 2004 patent arrangement with Roche delayed ENBREL biosimilars.
- Patent fights over biosimilars: Regeneron is suing over PAVBLU, and Bristol-Myers Squibb and Ono sued in September 2026 over Amgen's OPDIVO biosimilar candidate ABP 206 (see Current quarter).
6. Manufacturing concentration and supply. The Puerto Rico plant handles a substantial majority of commercial production and is exposed to hurricanes and earthquakes. Many of the contract manufacturers that came with Horizon are single-source, including the one that makes all KRYSTEXXA drug substance in Israel, which is affected by the Middle East conflict. A single supplier makes the SureClick autoinjector used for Repatha and ENBREL.
7. Customer and payer concentration. Three wholesalers account for most U.S. sales. The six largest PBMs, all now part of major insurers, handle 94% of prescription claims according to a 2024 FTC interim report, and CVS, Express Scripts and UnitedHealth Group run rebate management organizations that add to their leverage over discounts and formulary access.
8. Cybersecurity and AI. Attacks on cloud services, third-party vendors and AI-enabled threats are rising. Amgen disclosed a material cybersecurity incident in July 2026 (see Current quarter).
9. Acquisitions and leverage. Large deals bring integration and impairment risk. Otezla's intangible asset was written down by $1.2 billion in 2025 after its early selection for Medicare price setting, and the debt raised for Horizon led the rating agencies to downgrade Amgen. Senior notes were rated BBB+ (S&P), Baa1 (Moody's) and BBB+ (Fitch) at December 31, 2025.
Management's discussion: fiscal 2025
From the FY2025 Form 10-K (accession 0000318154-26-000010), Item 7.
| ($ millions, except EPS) | 2025 | 2024 | Change |
|---|---|---|---|
| Product sales | 35,148 | 32,026 | +10% |
| Other revenues | 1,603 | 1,398 | +15% |
| Total revenues | 36,751 | 33,424 | +10% |
| Operating expenses | 27,671 | 26,166 | +6% |
| Operating income | 9,080 | 7,258 | +25% |
| Net income | 7,711 | 4,090 | +89% |
| Diluted EPS | $14.23 | $7.56 | +88% |
Sales. Product sales grew 10% on 13% volume growth, partly offset by a 3% decline in net selling price. U.S. volume rose 13% and ROW volume 14%. Growth came mainly from Repatha (+36% to $3.0 billion), EVENITY (+34%), TEZSPIRE (+52%) and BLINCYTO (+28%), with IMDELLTRA and PAVBLU also contributing. The main drag was ENBREL, down 33% to $2.2 billion as its net selling price fell 36% on a higher 340B mix, the Medicare Part D redesign and higher commercial discounts. Prolia still grew 1% despite its February 2025 U.S. patent expiry. Other revenues rose 15%, mainly on royalties.
Costs.
- Cost of sales: fell to 32.8% of total revenues from 38.5%, as amortization of Horizon intangibles and the inventory step-up declined and manufacturing costs fell.
- R&D: rose 22% to $7.3 billion, driven by later-stage programs including MariTide; the 10-K notes the increase includes 2025 business development activity.
- Other operating expenses: included $1.2 billion of Otezla intangible impairments.
Below the line. Interest expense fell to $2.8 billion as Amgen paid down debt. Other income rose to $2.7 billion, mainly on unrealized gains on the BeOne stake. The tax rate was 14.1%.
Cash and capital.
- Cash flow: operating cash flow was $10.0 billion, down from $11.5 billion, largely because of working-capital timing after strong fourth-quarter 2024 collections. Capital expenditures were $1.9 billion.
- Debt: Amgen retired $6.0 billion of debt: $5.0 billion of repayments and $1.0 billion of principal repurchased for $683 million, a $264 million gain.
- Dividends and buybacks: dividends paid totaled $5.1 billion, at $2.38 per quarter. There were no buybacks in 2025, and $6.8 billion of authorization remained.
- Year-end balance sheet: cash was $9.1 billion, total debt (carrying value) $54.6 billion and stockholders' equity $8.7 billion. Equity is low because cumulative buybacks and dividends have left an accumulated deficit.
- Commitments: purchase obligations were about $6.9 billion, and potential future payments to partners could total up to about $7.2 billion.
2026 outlook (as stated in the 10-K). Management expected volume growth to be partly offset by net price declines, accelerated erosion of Prolia and XGEVA, the usual seasonally weak first quarter for ENBREL, Otezla, Repatha, TEZSPIRE and KRYSTEXXA, a mid-single-digit decline in Repatha's net selling price, and about $2.6 billion of capital spending.
Current quarter: Q3 2026 (three months ended September 30, 2026)
From the Q3 2026 Form 10-Q (accession 0000318154-26-000155); free cash flow, non-GAAP figures, guidance and pipeline updates are from the third-quarter earnings release furnished on Form 8-K (accession 0000318154-26-000153).
| ($ millions, except EPS) | Q3 2026 | Q3 2025 | Change | 9M 2026 | 9M 2025 | Change |
|---|---|---|---|---|---|---|
| U.S. product sales | 7,259 | 6,751 | +8% | 20,022 | 18,737 | +7% |
| ROW product sales | 2,624 | 2,386 | +10% | 7,616 | 7,044 | +8% |
| Total revenues | 10,365 | 9,557 | +8% | 29,037 | 26,885 | +8% |
| Operating income | 3,710 | 2,526 | +47% | 9,890 | 6,360 | +56% |
| Net income | 3,864 | 3,216 | +20% | 8,058 | 6,378 | +26% |
| Diluted EPS | $7.08 | $5.93 | +19% | $14.79 | $11.77 | +26% |
Volume drove the quarter. Product sales rose 8% to $9.88 billion, driven by volume: U.S. volume grew 8% and ROW volume 16%, led by Repatha, UPLIZNA, EVENITY, IMDELLTRA, TEZSPIRE and PAVBLU. Other revenues rose 15% to $482 million on higher royalties and partner revenue. The release says 17 products grew at least at a double-digit rate and 17 are on a run rate above $1 billion a year.
Growth products:
- Repatha: $1,085 million, +37%, on volume; U.S. sales rose 51%.
- EVENITY: $751 million, +39%, on volume.
- TEZSPIRE: $538 million, +43%, on volume.
- BLINCYTO: $496 million, +27%, mainly on volume.
- UPLIZNA: $451 million versus $155 million, mainly on volume.
- KRYSTEXXA: $419 million, +31%, mainly on a higher net selling price.
- IMDELLTRA/IMDYLLTRA: $406 million versus $178 million, on volume.
- Vectibix: $335 million, +18%.
- PAVBLU: $300 million, +41%: volume rose 71% while net price fell 18%.
- Established products (Aranesp, Neulasta, Parsabiv): $606 million, +14%, on a 19% higher net selling price.
Declining or flat products:
- Prolia: $632 million, -45%, as biosimilars spread: volume fell 23%, with the rest of the decline split equally between lower net price and changes to estimated sales deductions.
- XGEVA: $288 million, -47%, on 32% lower volume and an 11% lower net price.
- Otezla: $481 million, -18%, on 13% lower volume, 9% unfavorable sales-deduction changes and a 4% lower net price. ROW sales fell 53% after European generic entry.
- TEPEZZA: $526 million, -6%, on lower wholesaler inventory; U.S. sales fell 15% while ROW roughly doubled to $85 million.
- ENBREL: $611 million, +5%, but only because of 15% favorable sales-deduction changes and 8% higher inventory. Its net selling price fell 14% under Medicare Part D price setting, and volume fell. Over nine months ENBREL is down 11%.
- KYPROLIS: $330 million, -8%, on lower volume. MVASI: $168 million, -21%.
- Nplate: $472 million, +3%; excluding U.S. government orders ($65 million versus $90 million), it grew 11%.
- TAVNEOS: $105 million, -2%.
Margins widened because acquisition accounting is rolling off.
- Cost of sales: fell to 26.9% of total revenues from 32.2%, on lower amortization of acquisition-related assets ($889 million of intangible amortization versus $1.1 billion) and lower manufacturing costs, partly offset by higher profit-share expense and sales mix. Remaining intangible amortization is scheduled at $0.9 billion for the fourth quarter of 2026, $3.5 billion in 2027 and $2.8 billion in 2028.
- R&D: rose 11% to $2.11 billion, driven by Research and Early Pipeline spending including business development.
- SG&A: fell 2% to $1.68 billion on lower general and administrative costs.
- Other operating expenses: $76 million, versus $329 million a year earlier, when a $400 million Otezla impairment was booked. The 2026 quarter included intangible asset impairment charges ($59 million in the release's reconciliation).
- Non-operating items: interest expense was $653 million versus $685 million. Other income fell to $1.63 billion from $2.08 billion because the unrealized gain on BeOne shares was smaller ($1.5 billion versus $1.9 billion).
- Tax rate: 17.5%, versus 18.0%.
- Non-GAAP view: non-GAAP operating margin was 47.3% of product sales versus 47.1%, and non-GAAP EPS was $6.45 versus $5.64.
Business development. Contingent consideration owed to former owners of acquired assets rose to $367 million at September 30, 2026 from $161 million at year-end, including $192 million of additions in the third quarter, which the 10-Q attributes to business development activity in 2025 and 2026 alongside the 2021 Teneobio acquisition. The 10-Q does not name the counterparty, and no acquisition is shown in the cash flow statement.
Cash flow and balance sheet.
- Operating cash flow: $4.24 billion in the quarter versus $4.68 billion; capital spending was $587 million, so free cash flow was $3.65 billion versus $4.25 billion. The release attributes the decline to working capital, the prior-year quarter having benefited from the timing of rebates and collections. For nine months, operating cash flow was $10.4 billion versus $8.4 billion (the 2025 period included the final $1.8 billion repatriation-tax payment) and free cash flow $8.6 billion versus $7.1 billion.
- Debt: in the quarter Amgen repaid in full the $1.8 billion term loan left from the Horizon financing and the $1.25 billion 2.60% notes. Earlier in 2026 it issued $4.0 billion of notes due 2031–2056, repaid the €750 million 2.00% euro notes ($833 million after the swap) and repurchased $324 million of principal for $233 million, a $90 million gain. Total debt (carrying value) was $54.0 billion at September 30, 2026, of which $2.4 billion is current; the £475 million 5.50% sterling notes are the remaining 2026 maturity. The $4.0 billion revolving credit facility, extended to March 2029, was undrawn.
- Cash and equity: cash and equivalents were $13.2 billion, down from $14.0 billion at June 30, as $3.1 billion of debt repayments and $1.4 billion of dividends exceeded the quarter's operating cash flow. Stockholders' equity rose to $14.4 billion from $8.7 billion at year-end.
- Shareholder returns: no shares were repurchased, leaving $6.8 billion of authorization. The quarterly dividend is $2.52, up 6%.
Outlook. The 10-Q expects volume growth from certain brands to be partially offset by net selling price declines for the rest of 2026, continued erosion of Prolia and XGEVA, and further Otezla price declines once Medicare price setting starts in 2027. On November 3, 2026 Amgen raised its full-year 2026 guidance to total revenues of $38.9–$39.7 billion (from $38.2–$39.4 billion in August), GAAP EPS of $18.34–$19.28 and non-GAAP EPS of $22.90–$23.70, keeping capital expenditures at about $2.6 billion and share repurchases at up to $3.0 billion.
Policy backdrop. The Administration imposed Section 232 tariffs on certain patented pharmaceuticals in April 2026; Amgen's relief, granted in December 2025, runs for approximately three years from December 2025. Management also says geopolitical conflict has made energy and transport markets more volatile and disrupted supply chains.
Pipeline in the quarter.
- IMDELLTRA: the Phase 3 DeLLphi-305 study met its primary endpoint: adding IMDELLTRA to IMFINZI as first-line maintenance in extensive-stage small cell lung cancer cut the risk of death by 58% and of progression or death by 66%. In September the FDA shortened the recommended monitoring time after the first two doses to 6–8 hours from 22–24.
- Dazodalibep: the Phase 3 OASIZ-301 study in Sjögren's disease met its primary endpoint at week 48; the second Phase 3 study (OASIZ-303) is expected to complete in the fourth quarter of 2026.
- TEZSPIRE: the Phase 3 CROSSING study in eosinophilic esophagitis met its co-primary endpoints, with histologic remission in 64.8% and 68.9% of patients on the two doses versus 3.5% on placebo.
- Repatha: the European Commission broadened its label to adults with or at high risk of atherosclerotic cardiovascular disease, based on VESALIUS-CV.
- MariTide: a third type 2 diabetes Phase 3 study (MARITIME-T2D-3, versus semaglutide) began, and two more are to start in the fourth quarter of 2026.
- Biosimilars: the FDA accepted the application for ABP 206 (OPDIVO biosimilar) with action expected by year-end, and ABP 234 (KEYTRUDA biosimilar) met its primary and secondary endpoints.
- Other: daxdilimab is moving to Phase 3 after positive Phase 2 data in discoid lupus; TEPEZZA met both primary endpoints in a Japanese chronic thyroid eye disease study; two subcutaneous blinatumomab studies remain on FDA partial clinical hold.
TAVNEOS. Third-quarter TAVNEOS sales were $105 million. Amgen says it continues to engage with the FDA and believes the drug is effective with a favorable benefit-risk profile; its patent case against generic filers was stayed on July 29 pending the FDA Commissioner's decision.
Litigation in the quarter.
- PAVBLU / Regeneron: in August the West Virginia court refused to send Regeneron's 2024 and 2025 patent suits back to California, and Amgen asked the court to reconsider its July 7 ruling striking certain of Amgen's defenses and counterclaims.
- ABP 206: on September 8, Bristol-Myers Squibb, E. R. Squibb and Ono sued in Delaware alleging that Amgen's biosimilar application for ABP 206 infringes seven patents.
- ENBREL insurer suits: on August 17 the Ventura County court granted Amgen's demurrers to the Centene, Humana and Molina complaints; the plaintiffs have sought dismissal with prejudice so they can appeal.
- ChemoCentryx opt-out suits: on September 14 ChemoCentryx and its former CEO agreed to settle both RA Capital cases.
Cybersecurity incident. In July 2026 Amgen disclosed a material incident in which data, including proprietary data and patients' protected health information, was exfiltrated from cloud environments run by third-party providers. It has found no impact on its products, manufacturing or financial reporting systems and believes the incident is not reasonably likely to materially affect its financial condition or results (Form 8-K, accession 0000318154-26-000119).
Management. Thomas Dittrich, who succeeded Peter H. Griffith as Chief Financial Officer on September 1, 2026 under the transition announced in May (Form 8-K, accession 0000318154-26-000097), signed the Q3 10-Q as CFO.
Subsequent events (after September 30, 2026)
The Q3 2026 Form 10-Q (accession 0000318154-26-000155) has no separate subsequent-events note. The post-quarter developments below come from its notes and from Forms 8-K as cited.
No acquisitions, divestitures or new financings. No acquisition, divestiture, debt issuance or borrowing after September 30, 2026 is disclosed in the 10-Q or in any Form 8-K filed through November 9, 2026.
Dividend. In October 2026 the Board declared a quarterly dividend of $2.52 per share, payable in December 2026.
Board. On October 26, 2026 the Board appointed David W. Gibbs, former chief executive of Yum! Brands, as a director, bringing it to 13 members, 12 of them independent (Form 8-K, accession 0000318154-26-000144).
Litigation.
- Denosumab biosimilars: on October 2 and 5, 2026 Amgen added U.S. Patent No. 12,679,865 to its suits against Dr. Reddy's and Alkem; the defendants answered with counterclaims on October 23 and 26. No trial date is set.
- KYPROLIS: on October 6 the Delaware court adopted the construction proposed by Amgen subsidiary Onyx for the disputed claim term in its suit against Amneal; trial is set for July 28, 2027.
- PAVBLU / Regeneron: on October 27 the court dismissed with prejudice Regeneron's claims under two patents (Nos. 9,816,110 and 11,788,102), and Amgen's related counterclaims without prejudice; the claim construction hearing moved to December 1, 2026.
- Roofers securities class action (over disclosure of the IRS dispute): the court granted preliminary approval of the settlement on October 21, 2026, with a final-approval hearing set for March 2, 2027. The amount is not disclosed.
- ChemoCentryx securities matters: no objections were filed, and on October 29, 2026 the court approved the class settlement and dismissed the action with prejudice. RA Capital dismissed its two opt-out cases on October 19 under its settlement.
- ABP 206: Amgen's response to the Bristol-Myers Squibb complaint was due November 13, 2026.
AI synthesis of events in 12 filings
Filings that contain financial statements
Each earnings press release below (Exhibit 99.1 to a Form 8-K, Item 2.02) carries a consolidated statement of income and a consolidated balance sheet, with non-GAAP reconciliations and a free-cash-flow reconciliation. None carries a full cash flow statement.
- 8-K filed November 3, 2026, accession 0000318154-26-000153: income statement for the three and nine months ended September 30, 2026 (with 2025 comparatives); balance sheet at September 30, 2026 and December 31, 2025.
- 8-K filed August 4, 2026, accession 0000318154-26-000124: income statement for the three and six months ended June 30, 2026; balance sheet at June 30, 2026.
- 8-K filed April 30, 2026, accession 0000318154-26-000054: income statement for the three months ended March 31, 2026; balance sheet at March 31, 2026.
- 8-K filed February 3, 2026, accession 0000318154-26-000003: income statement for the fourth quarter and year ended December 31, 2025; balance sheet at December 31, 2025.
Earnings and guidance
- November 3, 2026, third-quarter 2026 results (accession 0000318154-26-000153). Total revenues rose 8% to $10.4 billion ($10,365 million vs. $9,557 million); product sales were $9,883 million vs. $9,137 million. GAAP diluted EPS was $7.08 vs. $5.93 and net income $3,864 million vs. $3,216 million. GAAP operating income rose from $2.5 billion to $3.7 billion (operating margin 37.5%, up 9.9 points), helped by lower acquisition-related amortization. Non-GAAP EPS was $6.45 vs. $5.64. Free cash flow was $3.7 billion vs. $4.2 billion a year earlier; the company attributed the decline to working-capital changes, with the prior-year quarter helped by the timing of rebates and collections. Cash was $13.2 billion and debt outstanding $54.0 billion at September 30, 2026. No shares were repurchased in the quarter. The third-quarter dividend was $2.52 per share (up 6% year over year), paid September 11, 2026.
- Full-year 2026 guidance raised again. The November release guides total revenues to $38.9 billion to $39.7 billion, GAAP EPS to $18.34 to $19.28 and non-GAAP EPS to $22.90 to $23.70, with a GAAP tax rate of 14.5% to 16.0% and a non-GAAP rate of 15.0% to 16.5%. Capital expenditures are about $2.6 billion and share repurchases are capped at $3.0 billion. Guidance path for revenues and non-GAAP EPS:
- February 3, 2026 (accession 0000318154-26-000003): revenues $37.0 billion to $38.4 billion; non-GAAP EPS $21.60 to $23.00.
- April 30, 2026 (accession 0000318154-26-000054): revenues $37.1 billion to $38.5 billion; non-GAAP EPS $21.70 to $23.10.
- August 4, 2026 (accession 0000318154-26-000124): revenues $38.2 billion to $39.4 billion; non-GAAP EPS $22.30 to $23.50; GAAP EPS $15.80 to $17.08.
- November 3, 2026: revenues $38.9 billion to $39.7 billion; non-GAAP EPS $22.90 to $23.70; GAAP EPS $18.34 to $19.28.
- Earlier 2026 quarters. Second-quarter revenues rose 10% to $10.1 billion (August 4, 2026). First-quarter revenues rose 6% to $8.6 billion (April 30, 2026). Full-year 2025 revenues rose 10% to $36.8 billion, with fourth-quarter revenues up 9% to $9.9 billion (February 3, 2026).
- Pipeline. The November release lists the MariTide (maridebart cafraglutide) Phase 3 program as ongoing, with the MARITIME-CV, MARITIME-OSA-1 and MARITIME-OSA-2 studies fully enrolled and two further type 2 diabetes Phase 3 studies to start in the fourth quarter of 2026. It also notes that the biosimilar candidate ABP 206 (nivolumab comparator) has a Biologics License Application accepted for FDA review.
Capital actions
- February 17-19, 2026, senior notes offering (accession 0001193125-26-059490). Amgen issued and sold $4.0 billion of senior notes on February 17, 2026: $1,000 million of 4.200% notes due 2031, $1,750 million of 4.850% notes due 2036, $500 million of 5.500% notes due 2046 and $750 million of 5.650% notes due 2056. Net proceeds were about $3,961 million. The notes are unsecured and registered under an effective shelf registration statement. Interest is paid semi-annually from August 19, 2026.
- Dividend. Quarterly dividend of $2.52 per share in each of the first three quarters of 2026 (the fourth quarter of 2025 dividend was $2.38 per share), per the earnings releases above.
- Buybacks. No shares were repurchased in the first, second or third quarter of 2026, per the earnings releases above.
Collaboration and legal
- January 30, 2026, Kyowa Kirin termination (accession 0001193125-26-030518). Amgen and Kyowa Kirin Co., Ltd. entered into a Termination Agreement ending their June 1, 2021 License and Collaboration Agreement. The termination becomes effective upon receipt of regulatory approval. The FY2025 Form 10-K (accession 0000318154-26-000010) reports that Hart-Scott-Rodino clearance was received in February 2026, that Kyowa Kirin assumes full responsibility for rocatinlimab worldwide in the first quarter of 2026, and that Amgen continues to manufacture it for an agreed transition period; the termination is therefore effective. Financial terms are not described in the filing.
Cybersecurity
- July 31, 2026, material cybersecurity incident (accession 0000318154-26-000119, Item 1.05). In July 2026 Amgen identified unauthorized activity involving data in cloud environments hosted by third-party providers. Some data, including proprietary data and patient protected health information, was exfiltrated. The company determined the incident material on July 29, 2026 but stated it did not believe it is reasonably likely to have a material impact on financial condition or results of operations, and had not identified any impact on products, manufacturing or financial reporting systems. The investigation was ongoing and the company said it would amend the filing as further information is determined. No amendment is among the filings reviewed.
Management and board
- April 22, 2026 (accession 0000318154-26-000048). David M. Reese, executive vice president and Chief Technology Officer, will retire effective June 30, 2026. His responsibilities were redistributed from June 1, 2026 among James Bradner (Research and Development, Artificial Intelligence and Data), Murdo Gordon (Global Markets and Policy) and Peter Griffith (Chief Financial Officer); Sean Bruich became senior vice president and Chief Technology Officer.
- May 19, 2026, CFO transition (accession 0000318154-26-000097). Chief Financial Officer Peter H. Griffith will retire as CFO effective August 31, 2026 and remain an executive vice president until January 31, 2027. Thomas Dittrich, previously Chief Financial Officer of Galderma Group AG, joined as an executive vice president on July 1, 2026 and became Executive Vice President and Chief Financial Officer on September 1, 2026. His package includes a CHF 1,070,000 base salary, one-time awards of CHF 4,700,000 in restricted stock units, a CHF 4,000,000 cash bonus and a CHF 5,800,000 two-year retention bonus.
- May 19-20, 2026, annual meeting (accession 0001193125-26-232786). All 12 director nominees were elected, executive compensation was approved on an advisory basis, Ernst & Young LLP was ratified as auditor for 2026, and a stockholder proposal to require an independent board chairman was not approved.
- October 26-27, 2026 (accession 0000318154-26-000144). David W. Gibbs, former Chief Executive Officer of Yum! Brands, was appointed a director, effective immediately, joining the Audit and Compensation committees. The board now has 13 directors, 12 of them independent.
Not reflected in these filings
No acquisition or merger agreement, signed or closed, appears in the 8-K filings reviewed for the period from May 2025 through November 2026. No Form 8-K item was filed for Dark Blue Therapeutics, Ltd., which the FY2025 Form 10-K (accession 0000318154-26-000010) risk factors refer to as one of "our acquisitions", alongside ChemoCentryx and Horizon. No filing reviewed discloses its price, terms or closing date.
Financials
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. A figure with no link was either derived by AI, such as a margin, free cash flow or a trailing-twelve-month total, or taken from a filing that does not tag its numbers, such as an earnings release.
About this file
| Ticker | AMGN |
|---|---|
| CIK | 0000318154 |
| Company | Amgen Inc. |
| Business type | biopharmaceutical |
| Schema template | standard (product sales and total revenues / cost of sales / operating income / net income, plus product-level and U.S. versus rest-of-world product sales, which is how a single-segment biotechnology company is read) |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual dollars (not millions); share counts in actual shares; per-share figures in dollars |
AMGN annual income statement, balance sheet and cash flow
Taken from the SEC filings and normalized to actual dollars.
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 10-K | 10-K | 10-K |
| Income statement | |||
| Product sales | 35,148,000,000 | 32,026,000,000 | 26,910,000,000 |
| Other revenues | 1,603,000,000 | 1,398,000,000 | 1,280,000,000 |
| Total revenues | 36,751,000,000 | 33,424,000,000 | 28,190,000,000 |
| Cost of sales | 12,037,000,000 | 12,858,000,000 | 8,451,000,000 |
| Research and development | 7,272,000,000 | 5,964,000,000 | 4,784,000,000 |
| Selling general and administrative | 7,050,000,000 | 7,096,000,000 | 6,179,000,000 |
| Other operating expenses | 1,312,000,000 | 248,000,000 | 879,000,000 |
| Total operating expenses | 27,671,000,000 | 26,166,000,000 | 20,293,000,000 |
| Operating income | 9,080,000,000 | 7,258,000,000 | 7,897,000,000 |
| Interest expense net | -2,755,000,000 | -3,155,000,000 | -2,875,000,000 |
| Other income expense net | 2,651,000,000 | 506,000,000 | 2,833,000,000 |
| Income before income taxes | 8,976,000,000 | 4,609,000,000 | 7,855,000,000 |
| Provision for income taxes | 1,265,000,000 | 519,000,000 | 1,138,000,000 |
| Net income | 7,711,000,000 | 4,090,000,000 | 6,717,000,000 |
| Basic EPS | 14.33 | 7.62 | 12.56 |
| Diluted EPS | 14.23 | 7.56 | 12.49 |
| Basic shares | 538,000,000 | 537,000,000 | 535,000,000 |
| Diluted shares | 542,000,000 | 541,000,000 | 538,000,000 |
| Balance sheet | |||
| Cash and cash equivalents | 9,129,000,000 | 11,973,000,000 | |
| Trade receivables net | 9,570,000,000 | 6,782,000,000 | |
| Inventories | 6,225,000,000 | 6,998,000,000 | |
| Other current assets | 4,133,000,000 | 3,277,000,000 | |
| Total current assets | 29,057,000,000 | 29,030,000,000 | |
| Property plant and equipment net | 7,913,000,000 | 6,543,000,000 | |
| Intangible assets net | 22,276,000,000 | 27,699,000,000 | |
| Goodwill | 18,680,000,000 | 18,637,000,000 | |
| Other noncurrent assets | 12,660,000,000 | 9,930,000,000 | |
| Total assets | 90,586,000,000 | 91,839,000,000 | |
| Accounts payable | 2,367,000,000 | 1,908,000,000 | |
| Accrued liabilities | 18,523,000,000 | 17,641,000,000 | |
| Current portion of long term debt | 4,599,000,000 | 3,550,000,000 | |
| Total current liabilities | 25,489,000,000 | 23,099,000,000 | |
| Long term debt | 50,005,000,000 | 56,549,000,000 | |
| Long term deferred tax liabilities | 1,366,000,000 | 1,616,000,000 | |
| Long term tax liabilities | 2,690,000,000 | 2,349,000,000 | |
| Other noncurrent liabilities | 2,378,000,000 | 2,349,000,000 | |
| Common stock and additional paid in capital | 34,023,000,000 | 33,533,000,000 | |
| Accumulated deficit | -25,107,000,000 | -27,590,000,000 | |
| Accumulated other comprehensive loss | -258,000,000 | -66,000,000 | |
| Total stockholders equity | 8,658,000,000 | 5,877,000,000 | |
| Total liabilities and stockholders equity | 90,586,000,000 | 91,839,000,000 | |
| Shares outstanding | 538,800,000 | 536,900,000 | |
| Total debt derived | 54,604,000,000 | 60,099,000,000 | |
| Total liabilities derived | 81,928,000,000 | 85,962,000,000 | |
| Cash flow | |||
| Depreciation amortization and other | 5,167,000,000 | 5,592,000,000 | 4,071,000,000 |
| Impairment of intangible assets | 1,200,000,000 | 159,000,000 | 851,000,000 |
| Stock based compensation | 494,000,000 | 530,000,000 | 431,000,000 |
| Operating cash flow | 9,958,000,000 | 11,490,000,000 | 8,471,000,000 |
| Cash paid for acquisitions | -53,000,000 | 0 | -26,989,000,000 |
| Capex | -1,858,000,000 | -1,096,000,000 | -1,112,000,000 |
| Investing cash flow | -1,943,000,000 | -1,046,000,000 | -26,204,000,000 |
| Net proceeds from issuance of debt | 0 | 0 | 27,777,000,000 |
| Extinguishment of debt | -683,000,000 | -659,000,000 | -647,000,000 |
| Repayment of debt | -5,000,000,000 | -3,600,000,000 | -1,454,000,000 |
| Repurchases of common stock | 0 | -200,000,000 | 0 |
| Dividends paid | -5,124,000,000 | -4,832,000,000 | -4,556,000,000 |
| Financing cash flow | -10,859,000,000 | -9,415,000,000 | 21,048,000,000 |
| Free cash flow | 8,100,000,000 | 10,394,000,000 | 7,359,000,000 |
| Product sales by product | |||
| Prolia | 4,414,000,000 | 4,374,000,000 | 4,048,000,000 |
| Repatha | 3,016,000,000 | 2,222,000,000 | 1,635,000,000 |
| Otezla | 2,265,000,000 | 2,126,000,000 | 2,188,000,000 |
| Enbrel | 2,226,000,000 | 3,316,000,000 | 3,697,000,000 |
| Evenity | 2,100,000,000 | 1,563,000,000 | 1,160,000,000 |
| Xgeva | 2,084,000,000 | 2,225,000,000 | 2,112,000,000 |
| Tepezza | 1,903,000,000 | 1,851,000,000 | 448,000,000 |
| Blincyto | 1,559,000,000 | 1,216,000,000 | 861,000,000 |
| Nplate | 1,524,000,000 | 1,456,000,000 | 1,477,000,000 |
| Tezspire | 1,478,000,000 | 972,000,000 | 567,000,000 |
| Kyprolis | 1,412,000,000 | 1,503,000,000 | 1,403,000,000 |
| Aranesp | 1,389,000,000 | 1,342,000,000 | 1,362,000,000 |
| Krystexxa | 1,340,000,000 | 1,185,000,000 | 272,000,000 |
| Vectibix | 1,175,000,000 | 1,045,000,000 | 984,000,000 |
| Other products | 7,263,000,000 | 5,630,000,000 | 4,696,000,000 |
| Total product sales | 35,148,000,000 | 32,026,000,000 | 26,910,000,000 |
| Product sales by geography | |||
| United states | 25,656,000,000 | 23,301,000,000 | 19,272,000,000 |
| Rest of world | 9,492,000,000 | 8,725,000,000 | 7,638,000,000 |
| Dividends | |||
| Dividends declared | 5,228,000,000 | 4,931,000,000 | 4,644,000,000 |
| Dividends declared per share | 9.66 | 9.13 | 8.64 |
AMGN quarterly income statement, balance sheet and cash flow
Taken from the SEC filings and normalized to actual dollars.
| Q3 2026 | Q3 2025 | |
|---|---|---|
| Fiscal quarter | 3 | 3 |
| Period start | 2026-07-01 | 2025-07-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | three months | three months |
| Source accession | 10-Q | 10-Q |
| Cash flow source accession | 0000318154-26-000153 | 0000318154-26-000153 |
| Income statement | ||
| Product sales | 9,883,000,000 | 9,137,000,000 |
| Other revenues | 482,000,000 | 420,000,000 |
| Total revenues | 10,365,000,000 | 9,557,000,000 |
| Cost of sales | 2,788,000,000 | 3,082,000,000 |
| Research and development | 2,111,000,000 | 1,900,000,000 |
| Selling general and administrative | 1,680,000,000 | 1,720,000,000 |
| Other operating expenses | 76,000,000 | 329,000,000 |
| Total operating expenses | 6,655,000,000 | 7,031,000,000 |
| Operating income | 3,710,000,000 | 2,526,000,000 |
| Interest expense net | -653,000,000 | -685,000,000 |
| Other income expense net | 1,629,000,000 | 2,080,000,000 |
| Income before income taxes | 4,686,000,000 | 3,921,000,000 |
| Provision for income taxes | 822,000,000 | 705,000,000 |
| Net income | 3,864,000,000 | 3,216,000,000 |
| Basic EPS | 7.14 | 5.98 |
| Diluted EPS | 7.08 | 5.93 |
| Basic shares | 541,000,000 | 538,000,000 |
| Diluted shares | 546,000,000 | 542,000,000 |
| Balance sheet | ||
| Cash and cash equivalents | 13,190,000,000 | |
| Trade receivables net | 10,353,000,000 | |
| Inventories | 6,389,000,000 | |
| Other current assets | 4,431,000,000 | |
| Total current assets | 34,363,000,000 | |
| Property plant and equipment net | 8,884,000,000 | |
| Intangible assets net | 19,536,000,000 | |
| Goodwill | 18,664,000,000 | |
| Other noncurrent assets | 14,601,000,000 | |
| Total assets | 96,048,000,000 | |
| Accounts payable | 2,946,000,000 | |
| Accrued liabilities | 17,887,000,000 | |
| Current portion of long term debt | 2,398,000,000 | |
| Total current liabilities | 23,231,000,000 | |
| Long term debt | 51,609,000,000 | |
| Long term deferred tax liabilities | 1,278,000,000 | |
| Long term tax liabilities | 2,934,000,000 | |
| Other noncurrent liabilities | 2,644,000,000 | |
| Common stock and additional paid in capital | 34,284,000,000 | |
| Accumulated deficit | -19,807,000,000 | |
| Accumulated other comprehensive loss | -125,000,000 | |
| Total stockholders equity | 14,352,000,000 | |
| Total liabilities and stockholders equity | 96,048,000,000 | |
| Shares outstanding | 540,900,000 | |
| Total debt derived | 54,007,000,000 | |
| Total liabilities derived | 81,696,000,000 | |
| Cash flow | ||
| Operating cash flow | 4,241,000,000 | 4,684,000,000 |
| Investing cash flow | -649,000,000 | -414,000,000 |
| Financing cash flow | -4,391,000,000 | -2,853,000,000 |
| Capex | -587,000,000 | -436,000,000 |
| Free cash flow | 3,654,000,000 | 4,248,000,000 |
| Product sales by product | ||
| Repatha | 1,085,000,000 | 794,000,000 |
| Prolia | 632,000,000 | 1,139,000,000 |
| Evenity | 751,000,000 | 541,000,000 |
| Tepezza | 526,000,000 | 560,000,000 |
| Enbrel | 611,000,000 | 580,000,000 |
| Otezla | 481,000,000 | 585,000,000 |
| Blincyto | 496,000,000 | 392,000,000 |
| Tezspire | 538,000,000 | 377,000,000 |
| Nplate | 472,000,000 | 457,000,000 |
| Krystexxa | 419,000,000 | 320,000,000 |
| Xgeva | 288,000,000 | 539,000,000 |
| Uplizna | 451,000,000 | 155,000,000 |
| Aranesp | 329,000,000 | 357,000,000 |
| Kyprolis | 330,000,000 | 359,000,000 |
| Vectibix | 335,000,000 | 284,000,000 |
| Imdelltra imdylltra | 406,000,000 | 178,000,000 |
| Other products | 1,733,000,000 | 1,520,000,000 |
| Total product sales | 9,883,000,000 | 9,137,000,000 |
| Product sales by geography | ||
| United states | 7,259,000,000 | 6,751,000,000 |
| Rest of world | 2,624,000,000 | 2,386,000,000 |
| Dividends | ||
| Dividends declared | 1,396,000,000 | 1,308,000,000 |
| Dividends declared per share | 2.52 | 2.38 |
AMGN year-to-date income statement and cash flow
Taken from the SEC filings and normalized to actual dollars.
| Nine months ended September 30, 2026 | Nine months ended September 30, 2025 | |
|---|---|---|
| Period start | 2026-01-01 | 2025-01-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | nine months | nine months |
| Source accession | 10-Q | 10-Q |
| Income statement | ||
| Product sales | 27,638,000,000 | 25,781,000,000 |
| Other revenues | 1,399,000,000 | 1,104,000,000 |
| Total revenues | 29,037,000,000 | 26,885,000,000 |
| Cost of sales | 8,343,000,000 | 9,061,000,000 |
| Research and development | 5,698,000,000 | 5,130,000,000 |
| Selling general and administrative | 5,027,000,000 | 5,098,000,000 |
| Other operating expenses | 79,000,000 | 1,236,000,000 |
| Total operating expenses | 19,147,000,000 | 20,525,000,000 |
| Operating income | 9,890,000,000 | 6,360,000,000 |
| Interest expense net | -1,983,000,000 | -2,102,000,000 |
| Other income expense net | 1,631,000,000 | 3,204,000,000 |
| Income before income taxes | 9,538,000,000 | 7,462,000,000 |
| Provision for income taxes | 1,480,000,000 | 1,084,000,000 |
| Net income | 8,058,000,000 | 6,378,000,000 |
| Basic EPS | 14.92 | 11.86 |
| Diluted EPS | 14.79 | 11.77 |
| Basic shares | 540,000,000 | 538,000,000 |
| Diluted shares | 545,000,000 | 542,000,000 |
| Cash flow | ||
| Depreciation amortization and other | 3,350,000,000 | 4,035,000,000 |
| Impairment of intangible assets | 63,000,000 | 1,200,000,000 |
| Stock based compensation | 368,000,000 | 369,000,000 |
| Operating cash flow | 10,432,000,000 | 8,355,000,000 |
| Capex | -1,812,000,000 | -1,216,000,000 |
| Investing cash flow | -1,934,000,000 | -1,250,000,000 |
| Net proceeds from issuance of debt | 3,964,000,000 | 0 |
| Extinguishment of debt | -233,000,000 | -683,000,000 |
| Repayment of debt | -3,883,000,000 | -5,000,000,000 |
| Dividends paid | -4,083,000,000 | -3,841,000,000 |
| Financing cash flow | -4,437,000,000 | -9,633,000,000 |
| Free cash flow | 8,620,000,000 | 7,139,000,000 |
| Product sales by product | ||
| Repatha | 2,914,000,000 | 2,146,000,000 |
| Prolia | 2,118,000,000 | 3,360,000,000 |
| Evenity | 2,027,000,000 | 1,501,000,000 |
| Tepezza | 1,592,000,000 | 1,446,000,000 |
| Enbrel | 1,511,000,000 | 1,694,000,000 |
| Otezla | 1,403,000,000 | 1,640,000,000 |
| Blincyto | 1,383,000,000 | 1,146,000,000 |
| Tezspire | 1,367,000,000 | 1,004,000,000 |
| Nplate | 1,314,000,000 | 1,139,000,000 |
| Krystexxa | 1,074,000,000 | 905,000,000 |
| Xgeva | 1,051,000,000 | 1,637,000,000 |
| Uplizna | 1,048,000,000 | 422,000,000 |
| Aranesp | 992,000,000 | 1,056,000,000 |
| Kyprolis | 974,000,000 | 1,061,000,000 |
| Vectibix | 960,000,000 | 856,000,000 |
| Imdelltra imdylltra | 952,000,000 | 393,000,000 |
| Other products | 4,958,000,000 | 4,375,000,000 |
| Total product sales | 27,638,000,000 | 25,781,000,000 |
| Product sales by geography | ||
| United states | 20,022,000,000 | 18,737,000,000 |
| Rest of world | 7,616,000,000 | 7,044,000,000 |
| Dividends | ||
| Dividends declared | 2,758,000,000 | 2,588,000,000 |
AMGN trailing twelve month income statement and cash flow
Derived by AI from the figures the filings report. No filing prints these, so none of them is linked.
| Twelve months ended September 30, 2026 | |
|---|---|
| Period start | 2025-10-01 |
| Period end | 2026-09-30 |
| Period type | trailing twelve months |
| Source accession | 10-Q |
| Derived from accessions | 10-K, 10-Q |
| Income statement | |
| Product sales | 37,005,000,000 |
| Other revenues | 1,898,000,000 |
| Total revenues | 38,903,000,000 |
| Cost of sales | 11,319,000,000 |
| Research and development | 7,840,000,000 |
| Selling general and administrative | 6,979,000,000 |
| Operating income | 12,610,000,000 |
| Net income | 9,391,000,000 |
| Diluted EPS | 17.25 |
| Cash flow | |
| Operating cash flow | 12,035,000,000 |
| Capex | -2,454,000,000 |
| Free cash flow | 9,581,000,000 |
| Dividends paid | -5,366,000,000 |
Adjustments
| Splits applied | none |
|---|---|
| ADR ratio | n/a |
| FX | none; Amgen reports in U.S. dollars |
Notes
- Annual figures for 2025, 2024 and 2023 are taken from the FY2025 Form 10-K (accession 0000318154-26-000010). The 10-K presents three years of income statement, cash flows and stockholders' equity but only two year-end balance sheets, so FY2023 carries no balance sheet.
- Quarterly figures for the three months ended September 30, 2026 and 2025, the nine-month year-to-date figures, and the September 30, 2026 balance sheet are taken from the Q3 2026 Form 10-Q (accession 0000318154-26-000155). The 10-Q does not present a September 30, 2025 balance sheet, so Q3 2025 carries none.
- The 10-Q's cash flow statement covers nine months only. The three-month cash flow figures for Q3 2026 and Q3 2025 (operating, investing and financing cash flow, capital expenditures and free cash flow) come from the Q3 2026 earnings release furnished as Exhibit 99.1 to the Form 8-K filed November 3, 2026 (accession 0000318154-26-000153), not from the 10-Q. That release's nine-month operating, investing and financing cash flows and capital expenditures equal the 10-Q's.
- Amgen reports one operating segment, human therapeutics, so the record is organized as a single consolidated business, with product sales broken out by product and by U.S. versus rest of world (ROW) as printed in the revenues note of each filing.
- Free cash flow follows Amgen's own definition: net cash provided by operating activities less capital expenditures. The quarterly and nine-month free cash flow figures are printed in the Q3 2026 earnings release; the nine-month figures equal the 10-Q's operating cash flow less its purchases of property, plant and equipment. The annual free cash flow is computed from the 10-K's cash flow statement in the same way; the FY2025 ($8,100 million) and FY2024 ($10,394 million) results equal the figures Amgen printed in its fourth-quarter 2025 earnings release (accession 0000318154-26-000003).
- Capital expenditures are the cash flow statement's 'Purchases of property, plant and equipment' (the earnings release labels the same amount 'Capital expenditures').
- Signs follow the filings: cash outflows and expense amounts printed in parentheses are stored as negative numbers, so interest_expense_net and capex are negative. other_income_expense_net is positive for net other income and negative for net other expense.
- total_debt_derived is the current portion of long-term debt plus long-term debt, at their balance-sheet carrying amounts. The balance sheet prints no total-liabilities line; total_liabilities_derived is the sum of total current liabilities, long-term debt, long-term deferred tax liabilities, long-term tax liabilities and other noncurrent liabilities, and with stockholders' equity it equals total assets in every period. The September 30, 2026 total debt of $54,007 million matches the $54.0 billion of debt outstanding stated in the Q3 2026 earnings release.
- No gross profit line is reported because Amgen does not present one. Its cost of sales includes most of the amortization of acquired intangible assets, which the 10-Q puts at $889 million for Q3 2026 and $1.1 billion for Q3 2025 ($2.7 billion and $3.4 billion for the nine months).
- Shares outstanding come from the statements of stockholders' equity, which print them in millions to one decimal place. Weighted-average basic and diluted shares are printed in whole millions on the income statement.
- Dividends declared, in total and per share, come from the statements of stockholders' equity. For the third quarters, the statements show $2.52 per share declared in 2026 and $2.38 in 2025. The nine-month totals ($2,758 million in 2026 and $2,588 million in 2025) cover two quarterly declarations each; the 10-Q's dividends note says the board declared $2.52 per share in December 2025, March 2026 and July 2026 for the first three quarters of 2026, so the December 2025 declaration falls in FY2025 and no nine-month per-share figure is given here. Dividends paid in cash are in the cash flow block.
- The 10-K names 14 principal products in its revenues note; the 10-Q names 16, adding UPLIZNA and IMDELLTRA/IMDYLLTRA, whose sales the 10-K includes in 'Other products'. 'Other products' therefore covers fewer products in the quarterly and nine-month periods than in the annual periods, and the two are not comparable. TEPEZZA and KRYSTEXXA came with the acquisition of Horizon on October 6, 2023, so FY2023 includes only their post-acquisition sales.
- The trailing-twelve-month view is derived, not printed by any filing: FY2025 from the 10-K, plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025, both from the 10-Q. Its diluted earnings per share ($17.25) is the same arithmetic applied to the published per-share figures ($14.23 + $14.79 - $11.77), not a figure Amgen reports.
- The 10-K states that certain prior-period amounts were reclassified to conform with the current presentation; the 2024 and 2023 figures here are as presented in the FY2025 10-K.
- No stock split, currency translation or ADR adjustment applies: Amgen reports in U.S. dollars, its common stock trades directly, and it has no stock split in the periods covered.
Uncertainties
- The trailing-twelve-month figures, including the $17.25 diluted earnings per share, are computed from the annual and nine-month columns and do not appear in any filing.
- Three-month cash flow figures for Q3 2026 and Q3 2025 rest on the Q3 2026 earnings release, because the 10-Q prints only nine-month cash flows.
Company details
| Name | Amgen Inc |
|---|---|
| Ticker | AMGN |
| CIK | 0000318154 |
| Exchange | Nasdaq |
| State | California |
| Incorporation | Delaware |
| SIC | 2836 |
| Office | Life Sciences |
| Industry | Biological Products, (No Diagnostic Substances) |
Fiscal period
| Fiscal year | 2026 |
|---|---|
| Fiscal period | Q3 |
| Tag | FY26Q3 |
| Period end | 2026-09-30 |
| Form | 10-Q |
| Accession | 0000318154-26-000155 |
| Fiscal year end | 1231 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Source |
|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-12-31 | 2026-02-13 | 0000318154-26-000010 | reported |
| quarterly | yes | 10-Q | 2026 | Q3 | FY26Q3 | 2026-09-30 | 2026-11-04 | 0000318154-26-000155 | facts |